Report Overview

The EU Rheumatoid Arthritis Therapeutics market stood at XX billion in 2019 and is projected to reach XX billion in 2028, exhibiting a CAGR of XX% during the forecast period

Rheumatoid arthritis (RA) is a chronic, disabling, inflammatory, autoimmune disease that affects approximately 0.41.0% of the population. Immune dysregulations, synovial membrane hyperplasia, activation of pro-inflammatory cells, and release of cytokines, such as interleukin (IL)-1, IL-6, and tumor necrosis factor-alpha (TNF-) are involved in the pathophysiological process. The initial drug treatment involved non-steroidal anti-inflammatory drugs (NSAID), e.g., aspirin or ibuprofen, to reduce joint pain and swelling; however, NSAIDs do not alter the course of the disease nor prevent joint destruction. Patients whose disease remains active despite NSAID were candidates for disease-modifying antirheumatic drugs (DMARD), the most widely used being methotrexate. The European Medicines Agency (EMA) has recommended granting a marketing authorization in the EU for Olumiant (baricitinib) for the treatment of adults with moderate to severe active rheumatoid arthritis. It is to be used to treat patients who have not responded adequately to, or who are unable to tolerate one or more diseasemodifying anti-rheumatic drugs (DMARDs). Olumiant, which is taken by mouth, can be used on its own or in combination with methotrexate



Market Growth Drivers

The increasing prevalence of Rheumatoid Arthritis in the EU and the launch of therapeutic novel agents are some of the factors that are driving the growth of the rheumatoid arthritis therapeutics market. Also, the growing geriatric population and rising awareness about arthritis and its prevention among patients and healthcare professionals are also expected to drive the EU Rheumatoid Arthritis Therapeutics market during the forecast period. Further, the presence of high-cost drugs and favorable reimbursement policies are the most prominent factors fueling the market growth